Risk-based monitoring (RBM) continues to transform clinical development using data insights delivered by innovative technology, enhanced processes and new roles to optimize execution. Biopharma is adopting RBM as the standard execution model for their studies.

QuintilesIMS is leading this evolution with an expanded RBM offering, Centralized Monitoring. Learn more about Centralized Monitoring and how we can help to reduce cost, save time and improve processes, while maintaining the highest levels of subject safety and data quality.